Viracta Therapeutics Past Earnings Performance
Past criteria checks 0/6
Viracta Therapeutics's earnings have been declining at an average annual rate of -9.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 169.3% per year.
Key information
-9.1%
Earnings growth rate
54.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -169.3% |
| Return on equity | -278.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Viracta Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -51 | 17 | 33 |
| 30 Sep 23 | 0 | -48 | 18 | 31 |
| 30 Jun 23 | 0 | -53 | 25 | 30 |
| 31 Mar 23 | 0 | -51 | 25 | 28 |
| 31 Dec 22 | 0 | -49 | 24 | 26 |
| 30 Sep 22 | 0 | -50 | 23 | 27 |
| 30 Jun 22 | 0 | -47 | 16 | 27 |
| 31 Mar 22 | 0 | -46 | 16 | 26 |
| 31 Dec 21 | 0 | -115 | 15 | 24 |
| 30 Sep 21 | 0 | -110 | 14 | 20 |
| 30 Jun 21 | 0 | -99 | 11 | 16 |
| 31 Mar 21 | 0 | -94 | 8 | 14 |
| 31 Dec 20 | 0 | -19 | 5 | 13 |
| 31 Dec 19 | 0 | -14 | 3 | 9 |
| 31 Dec 18 | 1 | -10 | 2 | 6 |
Quality Earnings: VIRX is currently unprofitable.
Growing Profit Margin: VIRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIRX is unprofitable, and losses have increased over the past 5 years at a rate of 9.1% per year.
Accelerating Growth: Unable to compare VIRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VIRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: VIRX has a negative Return on Equity (-278.72%), as it is currently unprofitable.